{ "schemaVersion": "deck-intelligence.v1", "id": "019de071-a0aa-74fc-b780-f72cc7f02158", "slug": "6af314fff9e6eaaf966098f4c73a6229", "title": "Mink Therapeutics | IPO Presentation Deck | 36 slides", "subtitle": "MiNK Therapeutics · 2021-10", "author": "MiNK Therapeutics", "date": "2021-10-01 00:00:00", "pageCount": 36, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7860465, "document": { "id": "019de071-a0aa-74fc-b780-f72cc7f02158", "slug": "6af314fff9e6eaaf966098f4c73a6229", "title": "Mink Therapeutics | IPO Presentation Deck | 36 slides", "rawTitle": "Mink Therapeutics | IPO Presentation Deck | 36 slides", "authorId": "mink-therapeutics", "authorName": "MiNK Therapeutics", "authorDisplay": "MiNK Therapeutics", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investment_bank", "label": "Investment bank" }, "fileName": "2021-10__mink-therapeutics__ipo__6af314ff.pdf", "sourceUrl": "https://www.slidebook.io/company/mink-therapeutics/presentation/6af314fff9e6eaaf966098f4c73a6229/", "sourceDate": "2021-10-15 00:00:00", "presentationDate": "2021-10-01 00:00:00", "ingestedAt": "2026-04-30 22:10:36.432704+00", "status": "ready", "pageCount": 36, "orientation": "landscape", "aspectRatio": 1.7860465, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2021-10__mink-therapeutics__ipo__6af314ff", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "IPO Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 36, "pagesIndexed": 36, "pagesWithImages": 36, "pagesWithMetadata": 36, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 125, "chartCount": 9, "metricSlides": 0, "toolMatches": 15, "documentToolMatches": 0, "frameworkMatches": 10, "arcMatches": 1, "beatMatches": 5, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "evidence": "The document follows a structure similar to the Sequoia Pitch, with sections on problem, solution, market size, product, business model, competition, financials, team, and the ask.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-17 03:23:31.24851+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 5, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 5, "name": "Problem", "beatId": "5edd5bbb-9ab3-4543-ba7f-3e32aefd902e", "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The document starts by presenting an overview of the problem MiNK Therapeutics aims to solve.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Solution", "beatId": "6fedce4d-a7ba-453c-a261-92793c99c63f", "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The document presents iNKT cells as a distinct solution in the cell therapy landscape.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 8, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 8, "name": "Pipeline", "beatId": "08b1170c-4f85-42d3-8be1-5abc101ba2e4", "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "beatType": null, "evidence": "The document outlines MiNK's pipeline and milestones.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 9, "name": "Team", "beatId": "6328cfad-a771-4225-b7ff-79cb33ec47cd", "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "The document presents the leadership team with a proven track record.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 35, "name": "Financials", "beatId": "df9de426-4cf6-4a90-b675-ffce826d458b", "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "beatType": { "name": "Financials", "slug": "sequoia-pitch-financials", "status": "active", "canonId": "019dd9b8-245d-74ce-8a5e-8094ec926a75", "version": 1, "description": null }, "evidence": "The document includes data on clinical trials and potential financial opportunities.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null, "categoryName": "Vision", "categorySlug": "vision" }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "1ca1e2a7-ac95-48e1-9860-5272696e9585", "evidence": "paragraph/paragraph: (Formerly AGENTus Therapeutics)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:38.514612+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "e1f77821-b1c4-4d0b-9c95-025d1aa31fd1", "evidence": "table/data: Issuer: MiNK Therapeutics, Inc.; Ticker / Exchange: INKT / Nasdaq Global Market; Base Offering Shares: 4,000,000; Price Range: $12.00 - $14.00; Gross Proceeds: $52.0 million; Option to Purchase Shares: 600,00", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:37.073988+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0fb38224-374e-41de-aa88-8d8de1d772c8", "evidence": "list/bullet: Allogeneic Invariant Natural Killer T (iNKT) Cell Platform Leveraging Both Adaptive and Innate Immune Systems", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:37.197577+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Venn diagram", "slug": "venn-diagram", "status": "active", "bestFor": null, "canonId": "019de52d-1f53-7290-96c8-79388c95fc17", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1995aea7-8fad-4457-8ad8-a2bf094aec10", "evidence": "diagram/venn: Venn diagram showing Innate vs Adaptive immunity with iNKT cells in the intersection", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:46:37.31889+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f56ee090-bc95-4478-8862-62d89e2c5455", "evidence": "table/data: Therapeutic Area, Indication, Next Milestone, Planned, What is Next?", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:56.042026+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "98327497-c36e-41ae-9987-5cd1b6712da5", "evidence": "table/data: Cancer Type: Head and Neck Cancer (SCCHN), Clinical Outcomes: ORR: 50%; Cancer Type: Non-Small Cell Lung Cancer (NSCLC), Clinical Outcomes: SD: 67% (4/6)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:56.164096+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "16f2c27a-54eb-4a8f-a63f-4baeeaef39ae", "evidence": "The slide contains a list/bullet points with specific details about the Bispecific iNKT Cell Engager Platform and CARDIS Platform.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:55.491833+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c1a380dc-2874-45a1-9aa8-b45792bd8705", "evidence": "The slide contains list/bullet points outlining 'Near-term (12-18mos) Catalysts and Milestones' and 'Financials'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:46:55.654325+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f051391d-867f-4df6-979f-1523781ceb63", "evidence": "The slide is titled 'Pioneering Allogeneic iNKT Cell Therapies for Oncology and Other Immune-Mediated Diseases' and provides a brief overview of the company's platform and milestones.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:55.73473+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "7d766d5d-b996-4d6f-a220-15117180155f", "evidence": "The slide features the company logo and is titled 'MiNK Therapeutics'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:55.816623+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6cbf9c02-04ca-4a80-81bc-84e3f553f41a", "evidence": "The slide contains list/bullet points describing 'MiNK as an Independent Operating Company'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:46:55.896715+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f3a9b9eb-eb0f-4ebf-94f1-8534a1f90931", "evidence": "The slide features list/bullet points outlining the benefits of the iNKT cell therapy, including 'Activation of proinflammatory immunity' and 'Reduce damaging hyperactivation of proinflammatory immune responses'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:46:55.977972+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f65e543c-8248-4575-85d9-037779799ab2", "evidence": "The slide features a table with data on 'Indication', 'AGENT-797 (iNKT cells)', and 'Endpoints' for various clinical trials.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:56.058036+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "e6068569-f76a-4756-bcb9-1983405a6ec6", "evidence": "The slide features a table with data on 'Indication', 'AGENT-797 (iNKT cells)', and 'Endpoints' for the Phase 1/2 clinical trial in Acute GVHD.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:56.138993+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "8bf5bbaf-23fb-404b-a096-1c0c8bd6044b", "evidence": "The slide features a table with data on 'Indication', 'AGENT-797 (iNKT cells)', and 'Endpoints' for the Phase 1/2 clinical trial in Virally Induced ARDS.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:56.219599+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "3b899866-32d9-4f09-b898-6e85ade19c84", "evidence": "Visual overlap of two categories (Innate and Adaptive) to show intersection (iNKT cells)", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 13:20:29.831+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "venn-diagram" }, { "matchId": "e82e5eba-fbfd-47db-b065-a64bdb7c3eaf", "evidence": "The pipeline table uses horizontal bars to represent the stage of development for each product.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:30.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "gantt-chart" }, { "matchId": "3f8fd9d0-66fe-49df-b82b-2f7a5518249c", "evidence": "Side-by-side comparison of current therapy vs new technology", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:27.666+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "contrast-pairs" }, { "matchId": "6c11ef8f-ea5a-4397-8b4a-2ae3ab1b79e0", "evidence": "The diagram shows iNKTs at the center influencing multiple peripheral biological processes.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:32.484+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "hub-spoke" }, { "matchId": "82d67a32-7e7c-456a-b8b6-3ffd39ff66ca", "evidence": "Circular flow diagram showing therapeutic intervention points", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 13:20:27.867+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "frameworkName": "process" }, { "matchId": "cdc2cd6d-98c3-44fe-b132-4b4ec2e0fbe5", "evidence": "The diagram maps the causal effects of iNKT cells on various biological targets.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 13:20:27.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "frameworkName": "causal-chain" }, { "matchId": "afdab6f4-a820-4015-a794-ad904d9c7845", "evidence": "Combines clinical trial status with preclinical survival data to support therapeutic thesis.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 13:20:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "evidence-matrix" }, { "matchId": "42357837-4d2b-44c3-9ceb-fa019e354794", "evidence": "The slide uses a table to compare the subject (iNKT cells) against competitors (T cells, NK cells) to highlight competitive advantage.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:28.18+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "frameworkName": "comparison_frame" }, { "matchId": "780872d3-6916-4a55-9d3c-80367eb1faef", "evidence": "The slide uses a bulleted list to summarize key company value propositions.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:29.124+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "frameworkName": "list-presentation" }, { "matchId": "764b76d7-e6d4-47c4-8ea4-a6fea6f03490", "evidence": "Use of a balance scale to represent immune modulation.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:35.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "frameworkName": "metaphor-analogy" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "title": "Includes former company name and date.", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/VliweEqG9lYECsnnhCCcDvNwemQ81NcKhLEH4Yn5YXU/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82YWYzMTRmZmY5ZTZlYWFmOTY2MDk4ZjRjNzNhNjIyOS9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 12, "componentCount": 3, "textChars": 80, "nDataPoints": 0, "notes": "Includes former company name and date.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:26.382+00", "seconds": 2.931, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/1", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-1", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.5, "x": 0.25, "y": 0.3 }, "kind": "image", "text": "MiNK Therapeutics", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.382+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae51fc12-0d1f-47b8-9d5a-edc9a0b5aec9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.3, "y": 0.6 }, "kind": "paragraph", "text": "(Formerly AGENTus Therapeutics)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.382+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "32941e2b-c013-401a-a15b-8664a82d1701", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.02, "y": 0.95 }, "kind": "source-note", "text": "Investor Meetings | October 2021", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.382+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4767f2c2-e6cf-4a86-9cf1-98772073368c", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "1ca1e2a7-ac95-48e1-9860-5272696e9585", "evidence": "paragraph/paragraph: (Formerly AGENTus Therapeutics)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:38.514612+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/olHYX-zYFxdnlfJbtxTddqDLudpvAXBc3krjSOdl_rg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82YWYzMTRmZmY5ZTZlYWFmOTY2MDk4ZjRjNzNhNjIyOS9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/27Cj923LcNpF-6BaXDDZP7PA6_m066lGhEZhhPRQUm0/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82YWYzMTRmZmY5ZTZlYWFmOTY2MDk4ZjRjNzNhNjIyOS9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/Z9dvWjgNfUjLYQU2NS7Zm8OHO2i442xQX7ntTP6eYWc/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82YWYzMTRmZmY5ZTZlYWFmOTY2MDk4ZjRjNzNhNjIyOS9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 3, "textChars": 2793, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:27.396+00", "seconds": 3.942, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/2", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-2", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "disclaimer", "text": "MiNK Therapeutics, Inc. (\"MiNK\" or the \"Company\") has filed a registration statement (File No. 333-259503), including a preliminary prospectus, with the Securities and Exchange Commission (the \"SEC\") in connection with the offering to which this presentation relates. Sales of securities of the Company offered pursuant to the registration statement may not be made or offers for such securities accepted prior to the registration statement becoming effective. Before making a decision to invest, you should read the prospectus in that registration statement and other documents that the Company has filed with the SEC for more complete information about the Company and the offering. You may obtain these documents for free by visiting EDGAR on the SEC's web site at www.sec.gov. Copies of the preliminary prospectus may also be obtained, when available, from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. This presentation may not be reproduced, forwarded to any person or published, in whole or in part.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.396+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6fdfbe1a-c82a-40b9-8e10-270cdcd3ac5d", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.9, "x": 0.05, "y": 0.6 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning: the therapeutic and curative potential of AGENT-797 and iNKT cells, future development plans and timelines and estimated treatment costs. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the preliminary prospectus filed with the SEC. Actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. When evaluating MiNK's business and prospects, careful consideration should be given to these risks and uncertainties. These statements speak only as of the date of this presentation, and MiNK undertakes no obligation to update or revise these statements.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.396+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9ced4bb9-1df6-420c-9802-256635ec72b4", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.15, "y": 0.05 }, "kind": "title", "text": "Disclaimer and Forward-Looking Statements", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.396+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c35ee96b-be43-42b0-9c8f-3ca31623a37a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "analysis", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 3, "textChars": 496, "nDataPoints": 6, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:25.759+00", "seconds": 2.16, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/3", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-3", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.7, "x": 0.25, "y": 0.45 }, "kind": "list", "text": "Fund the planned early development of our monotherapy and combination study of AGENT-797; Fund the development of AGENT-797 through completion of our Phase 1 clinical trial; Fund IND-enabling studies; Fund our process validation; Working capital", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:25.759+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ba0fc2b-b60f-40c9-85d0-51bcf1de5404", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "table", "text": "Issuer: MiNK Therapeutics, Inc.; Ticker / Exchange: INKT / Nasdaq Global Market; Base Offering Shares: 4,000,000; Price Range: $12.00 - $14.00; Gross Proceeds: $52.0 million; Option to Purchase Shares: 600,000; Lock-Up Period: 180 days", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:25.759+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "690d7b5f-5a8c-4b93-93d7-d148fa5f5b68", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.35, "y": 0.05 }, "kind": "title", "text": "Offering Summary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:25.759+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a5cfbefc-f95d-4493-a228-21e125c477f9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "e1f77821-b1c4-4d0b-9c95-025d1aa31fd1", "evidence": "table/data: Issuer: MiNK Therapeutics, Inc.; Ticker / Exchange: INKT / Nasdaq Global Market; Base Offering Shares: 4,000,000; Price Range: $12.00 - $14.00; Gross Proceeds: $52.0 million; Option to Purchase Shares: 600,00", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:37.073988+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 1, "componentCount": 1, "textChars": 8, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:25.178+00", "seconds": 1.535, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/4", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-4", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.24, "x": 0.38, "y": 0.45 }, "kind": "title", "text": "Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:25.178+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "853cffb5-b6fc-4b9b-97d9-7fafa3b189c7", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "setup", "title": "The slide uses a list-based summary format to outline the company's core value propositions.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 3, "textChars": 625, "nDataPoints": 1, "notes": "The slide uses a list-based summary format to outline the company's core value propositions.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:26.011+00", "seconds": 2.362, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/5", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-5", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.12, "x": 0.02, "y": 0.45 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.011+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1de4987-b620-47aa-bbc0-04c7997c13b5", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.85, "x": 0.1, "y": 0.25 }, "kind": "list", "text": "Allogeneic Invariant Natural Killer T (iNKT) Cell Platform Leveraging Both Adaptive and Innate Immune Systems\nMultiple Near Term Validation Milestones and Clinical Readouts for AGENT-797\nWholly-owned or Exclusively Licensed Pipeline Developing Both Native iNKT and Engineered iNKT Programs\nProprietary Manufacturing Process Designed to Facilitate Rapid iNKT Cell Production at Scale\nAbility to Investigate iNKT Combinations with Validated Immuno-oncology Therapies\nExperienced Leadership Team with Decades of Biopharmaceutical Expertise", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.011+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2b8a5ab7-c269-4fa0-bac9-c03b4a9da2c0", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Pioneering Allogeneic iNKT Cell Therapies for Oncology and Other Immune-Mediated Diseases", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.011+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "77e78e58-1dc4-4e5a-9d6c-f13046e046df", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0fb38224-374e-41de-aa88-8d8de1d772c8", "evidence": "list/bullet: Allogeneic Invariant Natural Killer T (iNKT) Cell Platform Leveraging Both Adaptive and Innate Immune Systems", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:37.197577+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Problem", "beatId": "5edd5bbb-9ab3-4543-ba7f-3e32aefd902e", "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The document starts by presenting an overview of the problem MiNK Therapeutics aims to solve.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "setup", "title": "The slide highlights specific financial figures ($50mm investment, $800mm in transactions) as evidence of the parent company's support.", "function": "other", "rawType": "unfair_advantage", "block": null, "metadata": { "slideType": "unfair_advantage", "slideTypeCanon": { "name": "Unfair advantage", "slug": "unfair_advantage", "status": "active", "canonId": "019de52d-0f56-744f-8bb4-c8a8cca240d6", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 2, "textChars": 862, "nDataPoints": 2, "notes": "The slide highlights specific financial figures ($50mm investment, $800mm in transactions) as evidence of the parent company's support.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:26.291+00", "seconds": 2.595, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/6", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-6", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "list", "text": "Agenus’ significant investment in the MiNK platform – ~$50mm to date as of June 30, 2021\nFoundational leadership at MiNK with key scientific and clinical achievements at Agenus since 2015 - advanced 17 discoveries to the clinic and secured ~$800mm in upfront and milestone payments and equity investments through partnering transactions\nExperts in iNKT cell biology and antibody engineering applicable to iNKT (e.g., CAR, iNKT engagers) with a record of success in delivering now-BLA stage antibodies at Agenus\nAccess to combination antibodies (PD-1, CTLA-4, TIGIT, etc) through Agenus’ pipeline of immuno-oncology antibodies and immune stimulating adjuvants\nExperienced cGMP manufacturing team and existing manufacturing facilities de-risks and differentiates from capital-intensive cell therapy companies", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.291+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cdb5be9e-313b-409b-b3a7-e89cf41f0f6c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "MiNK Is Favorably Positioned through its Roots in Agenus", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.291+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1be4060c-d713-464e-9703-ee944b4729c6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "resolution", "title": "The slide uses a Venn diagram to visually represent the dual nature of iNKT cells.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 33, "componentCount": 3, "textChars": 436, "nDataPoints": 0, "notes": "The slide uses a Venn diagram to visually represent the dual nature of iNKT cells.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:29.831+00", "seconds": 6.083, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/7", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-7", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.5, "x": 0.05, "y": 0.25 }, "kind": "diagram", "text": "Venn diagram showing Innate vs Adaptive immunity with iNKT cells in the intersection", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Venn diagram", "slug": "venn", "status": "active", "canonId": "019de52d-0463-710d-b529-cce18d828d2f", "version": 1, "description": null }, "framework": null }, "subkind": "venn", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.831+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bb5accda-6431-4037-8c40-ed901d16eb7c", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.38, "x": 0.58, "y": 0.3 }, "kind": "list", "text": "Distinct T cell population with rapid activation kinetics of innate immune cells and effector functions of adaptive T cells. Naturally promote protective immunity and limit pathological immune activation. Orchestrate innate and adaptive immune responses.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.831+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "863799d7-0b47-4368-92fd-39b2b861e814", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "iNKT Cells are Distinct in the Cell Therapy Landscape, Combining both Innate and Adaptive Immunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.831+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "87a6828b-04a7-46c0-81b6-0a9f3d65333d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Venn diagram", "slug": "venn-diagram", "status": "active", "bestFor": null, "canonId": "019de52d-1f53-7290-96c8-79388c95fc17", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1995aea7-8fad-4457-8ad8-a2bf094aec10", "evidence": "diagram/venn: Venn diagram showing Innate vs Adaptive immunity with iNKT cells in the intersection", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:46:37.31889+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "3b899866-32d9-4f09-b898-6e85ade19c84", "evidence": "Visual overlap of two categories (Innate and Adaptive) to show intersection (iNKT cells)", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 13:20:29.831+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "venn-diagram" } ], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "6fedce4d-a7ba-453c-a261-92793c99c63f", "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The document presents iNKT cells as a distinct solution in the cell therapy landscape.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "resolution", "title": "The slide uses a Gantt-style visualization for clinical trial phases.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 4, "textChars": 240, "nDataPoints": 0, "notes": "The slide uses a Gantt-style visualization for clinical trial phases.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:30.343+00", "seconds": 6.46, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/8", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-8", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.62, "w": 0.13, "x": 0.38, "y": 0.24 }, "kind": "chart", "text": "Progress bars indicating Preclinical status", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7d2c80fb-b62e-40c7-aa0c-22d45ea52c1f", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.35, "x": 0.04, "y": 0.94 }, "kind": "disclaimer", "text": "1. In the process of submitting Investigational New Drug (IND) application", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33ba63a8-ce7d-4d1e-8ce6-ff5d3221accb", "parentComponentId": null }, { "bbox": { "h": 0.76, "w": 0.92, "x": 0.04, "y": 0.14 }, "kind": "table", "text": "Pipeline table with columns: Target/Indication, Product, Preclinical, Phase 1, Phase 2, Phase 3, Next Milestone", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d38a5b74-1537-4d20-a00a-522248e101f2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.18, "x": 0.41, "y": 0.04 }, "kind": "title", "text": "Our Pipeline", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f74caadf-dc59-43e6-8dfc-9996d598a0b7", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "e82e5eba-fbfd-47db-b065-a64bdb7c3eaf", "evidence": "The pipeline table uses horizontal bars to represent the stage of development for each product.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:30.343+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "gantt-chart" } ], "arcBeats": [ { "to": 8, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Pipeline", "beatId": "08b1170c-4f85-42d3-8be1-5abc101ba2e4", "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "beatType": null, "evidence": "The document outlines MiNK's pipeline and milestones.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "setup", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 29, "componentCount": 4, "textChars": 218, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:26.403+00", "seconds": 2.429, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/9", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-9", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.05, "x": 0.06, "y": 0.2 }, "kind": "image", "text": "Headshots of management team members", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.403+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2223f991-dfd2-487e-9c50-5b2820c8ea25", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.6, "x": 0.35, "y": 0.2 }, "kind": "image", "text": "Corporate logos representing experience", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.403+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9cbfe220-9a39-4bf7-9e5d-cc5929010fef", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "table", "text": "Management Team and Board of Directors list with names, titles, and associated company logos.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.403+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "084f274e-338b-4e43-a1b7-cbbc22d06c2e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Dedicated Leadership Team with Proven Track Record", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.403+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6abbbd39-9e8e-4a76-b0f2-6f9779765435", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 9, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Team", "beatId": "6328cfad-a771-4225-b7ff-79cb33ec47cd", "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "The document presents the leadership team with a proven track record.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 1, "componentCount": 1, "textChars": 13, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:26.716+00", "seconds": 2.393, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/10", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-10", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.34, "x": 0.33, "y": 0.45 }, "kind": "title", "text": "Manufacturing", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.716+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9785f4ca-d9f8-4789-8855-9c1d4afb0010", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "evidence", "title": "Includes a flow cytometry plot and a dose-response killing assay.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 6, "textChars": 249, "nDataPoints": 2, "notes": "Includes a flow cytometry plot and a dose-response killing assay.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:28.369+00", "seconds": 3.618, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/11", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-11", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.7, "x": 0.15, "y": 0.8 }, "kind": "callout", "text": "Current Manufacturing Process Generates Tens of Billions of Cells", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d6f19227-8c7f-4e46-b3a6-679f3ec6b569", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.25, "x": 0.65, "y": 0.3 }, "kind": "chart", "text": "Expanded iNKT cells kill target cells", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d2eea816-926b-424e-982e-644cb374cc7e", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.25, "x": 0.35, "y": 0.3 }, "kind": "chart", "text": "iNKT purity >99%", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Scatter plot", "slug": "scatter", "status": "active", "canonId": "019de52d-007d-72ec-8689-c79fb78e21a2", "version": 1, "description": null }, "framework": null }, "subkind": "scatter", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ed599244-93d2-4377-a8cf-75928e711495", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.2, "x": 0.1, "y": 0.35 }, "kind": "image", "text": "High yield manufacturing and robust cryopreservation", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7a0add29-3418-4598-994f-7b2d567df71f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.1, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "Source: MiNK internal data", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6b1b147c-cdcc-45d4-84fd-4bc9b187007d", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "MiNK Manufactured iNKTs Scale with Full Functionality", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.369+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e38ef4e-f51f-4d16-9ebf-3a8a9c3ea1a0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "setup", "title": "The slide uses a contrast-pairs framework to position the company's technology against the incumbent standard of care.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 4, "textChars": 246, "nDataPoints": 7, "notes": "The slide uses a contrast-pairs framework to position the company's technology against the incumbent standard of care.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:27.666+00", "seconds": 2.842, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/12", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-12", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.78 }, "kind": "callout", "text": "MiNK's iNKT Cells Are Off-the-Shelf, Scalable, and Can Be Efficiently Transported and Stored", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.666+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12bb741d-910e-4579-9cdc-96d255f5a9fb", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "list", "text": "Current CAR-T Cell Therapies vs iNKT Cells", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Comparison list", "slug": "comparison", "status": "active", "canonId": "019de52c-fce7-733e-99d3-030a104727bf", "version": 1, "description": null }, "framework": null }, "subkind": "comparison", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.666+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8eb6a4e5-f4c4-4cf4-ad21-534406d0a94a", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.05, "y": 0.94 }, "kind": "source-note", "text": "Source: Gilead and Novartis company filings; EvaluatePharma", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.666+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f966098a-3022-4bc2-8380-4591fdb098f1", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "iNKT Manufacturing Is a High-Yield Turn-Key Operation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.666+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "acb4c32f-431d-4f22-9d51-a9ad8d974ae8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "3f8fd9d0-66fe-49df-b82b-2f7a5518249c", "evidence": "Side-by-side comparison of current therapy vs new technology", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:27.666+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "contrast-pairs" } ], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 5, "componentCount": 1, "textChars": 68, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:26.855+00", "seconds": 1.857, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/13", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-13", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.8, "x": 0.1, "y": 0.35 }, "kind": "title", "text": "AGENT-797 Clinical Programs in Oncology and Immune-Mediated Diseases", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:26.855+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "92ec7db5-21dc-4522-ad1b-b58c3577987a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "resolution", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 4, "textChars": 618, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:28.15+00", "seconds": 2.955, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/14", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-14", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.84, "x": 0.08, "y": 0.81 }, "kind": "callout", "text": "Multiple Near Term Milestones and Clinical Readouts and Development Opportunities", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.15+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c09de49b-19e6-420a-81a7-1c167bc86280", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.04, "y": 0.93 }, "kind": "source-note", "text": "1. IND submission pending 2. In the process of expanding trial into ARDS secondary to influenza", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.15+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "38daa46f-a673-46d9-8c77-8e393d8d486d", "parentComponentId": null }, { "bbox": { "h": 0.58, "w": 0.92, "x": 0.04, "y": 0.21 }, "kind": "table", "text": "Therapeutic Area, Indication, Next Milestone, Planned, What is Next? Oncology, Solid Tumors, Phase 1 top-line readouts, H1 2022, Accelerated development... r/r Multiple Myeloma, Phase 1 top-line readouts, Q4 2021, Robust efficacy... Immune Mediated Diseases, GvHD, IND clearance, Q4 2021, Accelerated development... ARDS, Phase 1 top-line readouts, Q4 2021, Phase 2 expansion...", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.15+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7ab1af92-3249-4e58-917e-f3134f6937ca", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.74, "x": 0.13, "y": 0.05 }, "kind": "title", "text": "AGENT-797 (iNKT Cells) Clinical Development Milestones and Plans", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.15+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e31da41c-1c78-4c05-a370-3cbe81d204f9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f56ee090-bc95-4478-8862-62d89e2c5455", "evidence": "table/data: Therapeutic Area, Indication, Next Milestone, Planned, What is Next?", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:56.042026+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "resolution", "title": "The slide uses a hub-and-spoke diagram to illustrate the multi-faceted mechanism of action of iNKT cells.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 27, "componentCount": 3, "textChars": 321, "nDataPoints": 0, "notes": "The slide uses a hub-and-spoke diagram to illustrate the multi-faceted mechanism of action of iNKT cells.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:32.484+00", "seconds": 7.133, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/15", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-15", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.45, "x": 0.5, "y": 0.2 }, "kind": "diagram", "text": "iNKTs interacting with Tumor Lysis, MDSC, and T-cell/NK-cell populations", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.484+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33a7568d-6bf2-4e7b-b09e-f327b07437ef", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.45, "x": 0.03, "y": 0.23 }, "kind": "list", "text": "iNKT Anti-Cancer Benefit Through: Tumor lysis via TCR dependent and independent mechanisms (CD1d ligands, Stress-signals); Counteracting myeloid suppressor cells; Recruiting & activating NK & T cells; Cytokine secretion", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.484+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7f5206de-2f0d-4051-baee-d715ea332801", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.52, "x": 0.24, "y": 0.05 }, "kind": "title", "text": "iNKTs for Anti-Cancer Response", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.484+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0c77355c-f32b-4fc4-ba80-79c07bbcb0da", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "6c11ef8f-ea5a-4397-8b4a-2ae3ab1b79e0", "evidence": "The diagram shows iNKTs at the center influencing multiple peripheral biological processes.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:32.484+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "hub-spoke" } ], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 16, "type": "evidence", "title": "The right side shows a series of CT scan comparisons (pre-treatment vs. iNKT treated) illustrating tumor shrinkage.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 5, "textChars": 587, "nDataPoints": 6, "notes": "The right side shows a series of CT scan comparisons (pre-treatment vs. iNKT treated) illustrating tumor shrinkage.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:28.258+00", "seconds": 2.887, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/16", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-16", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.45, "x": 0.07, "y": 0.6 }, "kind": "callout", "text": "Favorable safety profile: One Grade 3 AE (n=33 patients in 4 trials); No serious cytokine release or neurotoxicity observed; Up to 1 billion cells per patient, comparable to approved cell therapies", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3ce1cb3a-53d1-478c-86eb-15c79c933c23", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.3, "x": 0.65, "y": 0.15 }, "kind": "image", "text": "CT scan comparison images showing tumor reduction", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d155b546-0971-4e32-82ef-32be649cbfcc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.07, "y": 0.92 }, "kind": "source-note", "text": "Source: Yamasaki et al. 2011, Takami et al 2018, Exley et al 2017. 1. 2x10^8 iNKT cells dosed in the trial depicted in the graphic on the right", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9dccc7c8-ea2b-467f-960f-98ca449ae5f3", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.45, "x": 0.07, "y": 0.215 }, "kind": "table", "text": "Cancer Type: Head and Neck Cancer (SCCHN), Clinical Outcomes: ORR: 50%; Cancer Type: Non-Small Cell Lung Cancer (NSCLC), Clinical Outcomes: SD: 67% (4/6)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ec39e8b-8c03-465b-a6be-445ed0e6b333", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.8, "x": 0.1, "y": 0.05 }, "kind": "title", "text": "Autologous iNKTs Show Benefit in Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.258+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bdbd9983-8336-487d-936a-b9524d00d0e3", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "98327497-c36e-41ae-9987-5cd1b6712da5", "evidence": "table/data: Cancer Type: Head and Neck Cancer (SCCHN), Clinical Outcomes: ORR: 50%; Cancer Type: Non-Small Cell Lung Cancer (NSCLC), Clinical Outcomes: SD: 67% (4/6)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:56.164096+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 17, "type": "resolution", "title": "The slide uses a circular process diagram to show the therapeutic mechanism of iNKT cells.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 430, "nDataPoints": 0, "notes": "The slide uses a circular process diagram to show the therapeutic mechanism of iNKT cells.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:27.867+00", "seconds": 2.45, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/17", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-17", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.8, "x": 0.1, "y": 0.2 }, "kind": "diagram", "text": "Circular process showing pre-conditioning leading to graft failure, with iNKTs positioned to prevent cancer relapse, graft failure, and GvHD.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.867+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "42e1cef6-f811-404d-8520-1f04f72bc462", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.22, "y": 0.43 }, "kind": "list", "text": "Direct tumor lysis; Recruitment of T & NK cells; Counteract myeloid suppression", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.867+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7c380cca-b6a9-4a81-930f-8e154fbd9079", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.7, "y": 0.65 }, "kind": "list", "text": "Tissue damage loss of immune diversity; Organ cytotoxicity (intestines, liver, lungs); Inferior Response to conditioning regimen(>65yrs)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.867+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b4a8fdd7-a77a-42df-880d-358d3def3a7c", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "iNKTs for Transplant Success, Acute GvHD Suppression, Anti-Cancer Response", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.867+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7d7e9117-2395-40f3-af0d-322363e3f0c4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "82d67a32-7e7c-456a-b8b6-3ffd39ff66ca", "evidence": "Circular flow diagram showing therapeutic intervention points", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 13:20:27.867+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "frameworkName": "process" } ], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 18, "type": "evidence", "title": "Includes a Kaplan-Meier survival curve showing efficacy of iNKT cells in bone marrow transplant models.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 519, "nDataPoints": 5, "notes": "Includes a Kaplan-Meier survival curve showing efficacy of iNKT cells in bone marrow transplant models.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:28.604+00", "seconds": 2.999, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/18", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-18", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.35, "x": 0.57, "y": 0.47 }, "kind": "chart", "text": "Kaplan-Meier survival curve showing iNKT treatment vs control in murine models", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.604+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d694eba1-8b42-4621-b10a-35d9282b67ce", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.38, "x": 0.04, "y": 0.28 }, "kind": "list", "text": "~20,000 children & adults are diagnosed with GvHD annually; over 50% of global cases are fatal. GvHD is a complication of bone marrow transplants. iNKT-cells target GvHD in tissues. MiNK intends to initiate in Q4 2021 a phase 1/2 trial.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.604+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a705e47e-0de3-463b-aaa7-b6f02ce708b3", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.35, "x": 0.56, "y": 0.85 }, "kind": "source-note", "text": "Yang, J et al. Transfusion 2010; Allo BM transplant (C57BL/6 -> DBA/2); 6 mice / Group", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.604+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "82f427a3-4922-43a4-ba40-5a4a78bbd454", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.56, "x": 0.22, "y": 0.04 }, "kind": "title", "text": "AGENT-797 Development in GvHD", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.604+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4c1e1c38-c45c-4a8a-88d1-9f3b54e7dc2e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.68, "x": 0.16, "y": 0.11 }, "kind": "title", "text": "Versatile cells for suppressing GvHD, fighting infection, and reducing relapse in patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.604+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c56963f9-8b13-4b76-ad2b-db31adf16685", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "resolution", "title": "The diagram uses a hub-and-spoke model to show how iNKT cells interact with various biological targets.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "sparse", "densityScore": 22, "componentCount": 3, "textChars": 237, "nDataPoints": 0, "notes": "The diagram uses a hub-and-spoke model to show how iNKT cells interact with various biological targets.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:27.881+00", "seconds": 2.229, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/19", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-19", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.5, "x": 0.45, "y": 0.2 }, "kind": "diagram", "text": "iNKT cell interaction diagram", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bf9a5785-435c-4305-aa06-bab67c056e11", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.4, "x": 0.05, "y": 0.3 }, "kind": "list", "text": "Naturally homing to virally infected tissues/cells; Killing inflammatory monocytes; Recruiting and activating NK and T cells; Potentially dampening pro-inflammatory cytokines", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3a6ba080-d8d2-4e1c-9572-4f2391216c1d", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.6, "x": 0.2, "y": 0.05 }, "kind": "title", "text": "iNKTs in ARDS and Viral Infections", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3d8255e3-3ce3-40cf-9c47-0b1acca9751f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "cdc2cd6d-98c3-44fe-b132-4b4ec2e0fbe5", "evidence": "The diagram maps the causal effects of iNKT cells on various biological targets.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 13:20:27.881+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "frameworkName": "causal-chain" } ], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "setup", "title": "The slide uses a Kaplan-Meier survival curve to demonstrate the efficacy of iNKT cells in a mouse model.", "function": "establish_context", "rawType": "context", "block": null, "metadata": { "slideType": "context", "slideTypeCanon": { "name": "Context (pitchdeck)", "slug": "context", "status": "active", "canonId": "019de52d-1094-779e-9590-e4603e6a191c", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 6, "textChars": 691, "nDataPoints": 1, "notes": "The slide uses a Kaplan-Meier survival curve to demonstrate the efficacy of iNKT cells in a mouse model.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:33.702+00", "seconds": 8.047, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/20", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-20", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.35, "x": 0.578, "y": 0.288 }, "kind": "chart", "text": "Activated iNKTs Prolong Survival in Severe Influenza", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "77d2a459-5c27-4701-93f8-769b5bfe015d", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.08, "x": 0.438, "y": 0.445 }, "kind": "image", "text": "iNKTs", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "17bf55dd-a5e4-47e4-918c-23320a82321e", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.41, "x": 0.04, "y": 0.28 }, "kind": "paragraph", "text": "Acute respiratory distress syndrome (ARDS) is inflammation driven respiratory failure in viral infections. Approximately 40% of patients with ARDS die of lung failure. iNKTs may dampen inflammatory cytokines (IL-1 & IL-6), protect epithelial cells from damage (IL-22), clear virus, and may prevent reinfection. Ongoing Ph1 trial in ARDS (in COVID-19) demonstrates safety up to 1Bn cells/dose; Phase 2 expansion of ARDS (COVID and influenza) underway", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4026b93-1a04-4003-9520-6eec4248bf6b", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.6, "x": 0.06, "y": 0.93 }, "kind": "source-note", "text": "Global Data GvHD Report 2020; Kok et al, J Leukocyte Biol, 2012", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "66ffdec3-578f-4e4e-a82a-b8db716c42d3", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.58, "x": 0.21, "y": 0.12 }, "kind": "title", "text": "Versatile cells for suppressing inflammatory cytokines and fighting infection", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "079d79b5-41f3-46c5-bfca-19c737a848ba", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.76, "x": 0.12, "y": 0.04 }, "kind": "title", "text": "iNKT Development in ARDS and Viral Infections", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "803d5c72-741e-4070-af61-75983d4c6e5b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "afdab6f4-a820-4015-a794-ad904d9c7845", "evidence": "Combines clinical trial status with preclinical survival data to support therapeutic thesis.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 13:20:33.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "evidence-matrix" } ], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 5, "componentCount": 2, "textChars": 45, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:27.728+00", "seconds": 1.927, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/21", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-21", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.78, "x": 0.11, "y": 0.35 }, "kind": "title", "text": "iNKT Biology and Our Approach", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fb7f7155-be9c-4f0e-9e93-83af520e72eb", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.38, "x": 0.31, "y": 0.45 }, "kind": "title", "text": "Preclinical Data", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:27.728+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1f900299-64ca-4aff-97a2-6d06bbc55ad9", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 22, "type": "setup", "title": "The table uses checkmarks and crosses to visually demonstrate the superiority of iNKT cells.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "sparse", "densityScore": 23, "componentCount": 3, "textChars": 263, "nDataPoints": 0, "notes": "The table uses checkmarks and crosses to visually demonstrate the superiority of iNKT cells.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:28.18+00", "seconds": 2.225, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/22", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-22", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.85 }, "kind": "callout", "text": "Our iNKT platform provides the opportunity to look beyond cancer into other life-threatening disease with high unmet needs", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.18+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "897f9b5b-295f-4cde-a2a8-f1e1448bed71", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "table", "text": "Comparison table of T cells, NK cells, and iNKT cells across various performance metrics.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.18+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bee9ca90-2559-4a52-bd1f-2149c5dfbbe9", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "iNKT Cells Have Benefits Beyond Other Cell Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.18+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "539bd2d0-c778-47ba-9285-55eb6d09ed70", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "42357837-4d2b-44c3-9ceb-fa019e354794", "evidence": "The slide uses a table to compare the subject (iNKT cells) against competitors (T cells, NK cells) to highlight competitive advantage.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:28.18+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "frameworkName": "comparison_frame" } ], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 23, "type": "evidence", "title": "The chart shows a rapid decline in blood circulation and sustained presence in bone marrow.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 6, "textChars": 480, "nDataPoints": 12, "notes": "The chart shows a rapid decline in blood circulation and sustained presence in bone marrow.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:32.951+00", "seconds": 6.989, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/23", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-23", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.07, "w": 0.82, "x": 0.09, "y": 0.2 }, "kind": "callout", "text": "MiNK iNKT Cells are present and active >35 days", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.951+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bcdccca6-ed1f-4cb3-887a-e5ffd409e90c", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.35, "x": 0.1, "y": 0.32 }, "kind": "chart", "text": "Line chart showing iNKT cell counts in bone marrow (yellow) and blood (red) over 35 days.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.951+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1275ab69-ddd4-472b-b155-6441eb5a9c7a", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.4, "x": 0.47, "y": 0.33 }, "kind": "list", "text": "Healthy mice – Xenograft model\n10 million AGENT-7971 cells injected\niNKT cells rapidly disappear from circulation\nMigrate to bone marrow and other tissues\nDetected for >35 days in bone marrow", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.951+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0778f8de-ac75-4d31-80ae-2ce1179ef5a0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.49, "y": 0.71 }, "kind": "source-note", "text": "1Research grade product derived from clinical donor produced using same process", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.951+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69dd56a0-c6fe-4bc8-add7-8ed58b387fd7", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.15, "y": 0.84 }, "kind": "source-note", "text": "Internal data: NOG-IL15 mice, Bone marrow", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.951+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "74189587-cc99-4f4e-bb04-ce403335cc38", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.58, "x": 0.21, "y": 0.04 }, "kind": "title", "text": "iNKT Cells Have Shown Persistence", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.951+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3253978-2757-45eb-bed9-56f8b2a942a6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 24, "type": "evidence", "title": "The chart shows a clear divergence between the control group (tumor alone) and the treatment group (tumor + iNKT) starting around day 15.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 5, "textChars": 436, "nDataPoints": 12, "notes": "The chart shows a clear divergence between the control group (tumor alone) and the treatment group (tumor + iNKT) starting around day 15.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:32.001+00", "seconds": 5.894, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/24", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-24", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "callout", "text": "Preclinical Studies with MiNK iNKT Cells Show Tumor Killing in Leukemia", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c85c081-dbde-4057-b626-c23ff9034f19", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.4, "x": 0.06, "y": 0.35 }, "kind": "chart", "text": "Tumor burden over time comparing tumor alone vs tumor + iNKT", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c4a8030-8015-489b-978a-16297b7e455c", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.45, "x": 0.5, "y": 0.35 }, "kind": "list", "text": "Nalm6-CD1d human leukemia xenograft model; 10 million AGENT-797 cells injected; Stay in circulation with tumor cells; Home to all tissues with tumor cells; iNKT cells present and active for >21 days; Reduce tumor burden", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e7d8c245-fa31-4e25-ab59-7bc82b9ca9cb", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.1, "y": 0.75 }, "kind": "source-note", "text": "Internal data: Nalm6-CD1d cells; leukemia model", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a9f9258-7011-472e-86eb-83100a013d96", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.2, "y": 0.05 }, "kind": "title", "text": "iNKT Cells Show Tumor Killing Potential", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:32.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c888e2a2-9206-42cb-940c-9cf55a33e549", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 25, "type": "evidence", "title": "The chart is a dot plot showing the number of metastases across six treatment groups (A-F). Group F shows the lowest number of metastases.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 5, "textChars": 700, "nDataPoints": 6, "notes": "The chart is a dot plot showing the number of metastases across six treatment groups (A-F). Group F shows the lowest number of metastases.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:29.363+00", "seconds": 3.086, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/25", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-25", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.8, "x": 0.1, "y": 0.2 }, "kind": "callout", "text": "Expanded and Activated iNKT Cells by α-GalCer (an iNKT Activating Lipid Ligand) Promotes Lung Tumor Clearance in Combination with Checkpoint Antibodies", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.363+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81ecbe3d-04fd-48ac-be5a-49b2b6052b8c", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.1, "y": 0.35 }, "kind": "chart", "text": "Dot plot showing number of metastases for groups A through F", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.363+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ea11dab1-f3df-4bd6-8f2a-ff1d53954a53", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.4, "x": 0.55, "y": 0.35 }, "kind": "list", "text": "B16-ova intravenous metastatic mouse model; Checkpoint resistant; Activated iNKT cells show effective tumor infiltration and cancer reduction; iNKT activation + PD1 and/or Fc enhanced CTLA-4 show nearly complete tumor control", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.363+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bf99a8b8-839c-42df-ac96-7e45c0a0d56c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "Source: Tanne et al - Presented at AACR 2020, April 2020; B16ova melanoma model resulting in lung \"metastases\" after intravenous injections; Mouse surrogates to match Agenus checkpoint antibodies", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.363+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "23240388-2ee0-4da9-b6e0-d3b82281b21d", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.1, "y": 0.05 }, "kind": "title", "text": "iNKT Cell Plus Checkpoints Show Tumor Clearance in Preclinical Models", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.363+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "77666bb5-7968-4ece-9be7-4adf269714fc", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 26, "type": "resolution", "title": "The slide uses a comparative structure to present two distinct technological approaches.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 5, "textChars": 585, "nDataPoints": 0, "notes": "The slide uses a comparative structure to present two distinct technological approaches.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:29.137+00", "seconds": 2.762, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/26", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-26", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.25, "x": 0.15, "y": 0.25 }, "kind": "image", "text": "Diagram of CAR structure on cell membrane", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.137+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "48966af8-cfd7-4c5f-aa84-3eaf178bd5d2", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.6, "y": 0.25 }, "kind": "image", "text": "Diagram of Bispecific iNKT cell engager connecting iNKT cell to tumor cell", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.137+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e3a40683-509d-4d3a-9178-0cbe496aa133", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.4, "x": 0.05, "y": 0.65 }, "kind": "list", "text": "CARDIS Platform: Hybrid of phage & proprietary Mammalian Display platforms; Direct functional selection; Fully human ScFv libraries; Optimized intracellular signaling.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.137+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "75a60f65-8b31-43ce-bfe7-41880c35f06c", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.4, "x": 0.55, "y": 0.65 }, "kind": "list", "text": "Bispecific iNKT Cell Engager Platform: Based on proprietary Agenus platform; Proprietary arms; Fully human ScFv libraries; Direct functional selection; Works with native/engineered cells; Established CMC.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.137+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9b5e65f4-ca1e-45ea-9b42-31d1c72d0c38", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "iNKT Cells Can Be Modified with CARs & Redirected with Bispecific Engagers to Enhance Tumor Killing", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.137+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84c7f12e-4386-4f75-88fa-34049e258154", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "16f2c27a-54eb-4a8f-a63f-4baeeaef39ae", "evidence": "The slide contains a list/bullet points with specific details about the Bispecific iNKT Cell Engager Platform and CARDIS Platform.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:55.491833+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 27, "type": "evidence", "title": "The chart shows tumor burden over time, comparing MiNK iNKT-CAR (red) against a BCMA-CAR reference (green) and untreated control (blue).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 5, "textChars": 429, "nDataPoints": 3, "notes": "The chart shows tumor burden over time, comparing MiNK iNKT-CAR (red) against a BCMA-CAR reference (green) and untreated control (blue).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:29.96+00", "seconds": 3.443, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/27", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-27", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.52, "w": 0.42, "x": 0.05, "y": 0.29 }, "kind": "chart", "text": "Tumor burden over time in OPM2 in vivo model", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.96+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "46bf3652-0fca-47ab-8cb0-e3e72ae31241", "parentComponentId": null }, { "bbox": { "h": 0.48, "w": 0.52, "x": 0.44, "y": 0.31 }, "kind": "list", "text": "MiNK's iNKT cells can be engineered to expand and enhance potential anti-cancer activity. Allo-BCMA-CAR iNKT: Equivalent tumor control to clinical BCMA-CAR, Manufacturable at scale, Allogeneic and cost-effective. Novel tumor stromal CAR iNKT program underway.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.96+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9327bfd6-0b47-4b32-af0f-1279a0aa9721", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.94, "x": 0.03, "y": 0.21 }, "kind": "paragraph", "text": "MiNK cells engineered BCMA-CAR-iNKT", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.96+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "478625c8-3d16-4bf2-bb23-3bb2752b01ae", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.35, "x": 0.1, "y": 0.87 }, "kind": "source-note", "text": "Internal preclinical data in OPM2 in vivo model", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.96+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "77cbf3f0-e069-4c83-8738-169e658846aa", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.76, "x": 0.12, "y": 0.05 }, "kind": "title", "text": "Allogeneic CAR-iNKT Cells show tumor control", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.96+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "877f4e7d-a290-423b-aacd-b40050f46fa0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 28, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 0, "componentCount": 1, "textChars": 7, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:29.362+00", "seconds": 2.78, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/28", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-28", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.14, "w": 0.24, "x": 0.38, "y": 0.43 }, "kind": "title", "text": "Summary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.362+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "806f214a-22e3-4177-8d1b-3053eaaf7c9d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 29, "type": "resolution", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 26, "componentCount": 3, "textChars": 307, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:28.769+00", "seconds": 2.102, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/29", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-29", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.92, "x": 0.04, "y": 0.44 }, "kind": "list", "text": "Near-term (12-18mos) Catalysts and Milestones: Q4'21 Phase 1 data; 1H'22 Phase 1 safety; Q4'21 Phase 1/2 expansion; 2022 IND clearance; 2H'22 Phase 1 read-out; Potential partnerships", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.769+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3db05674-668b-4437-9169-c9787ce7ab18", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.56, "x": 0.04, "y": 0.18 }, "kind": "list", "text": "Financials: IPO planned to enable cash runway through end of 2023; No significant spend needed for manufacturing", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.769+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "70e775eb-9e93-4927-85b4-42d98b7eaa21", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.24, "x": 0.38, "y": 0.05 }, "kind": "title", "text": "Looking Ahead", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:28.769+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5ec2c27-6b0e-4a13-86f2-69889f2ba175", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c1a380dc-2874-45a1-9aa8-b45792bd8705", "evidence": "The slide contains list/bullet points outlining 'Near-term (12-18mos) Catalysts and Milestones' and 'Financials'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:46:55.654325+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 30, "type": "setup", "title": "The slide uses a list-based summary format to highlight key value drivers.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 3, "textChars": 446, "nDataPoints": 1, "notes": "The slide uses a list-based summary format to highlight key value drivers.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:29.124+00", "seconds": 2.257, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/30", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-30", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.15, "x": 0.02, "y": 0.4 }, "kind": "image", "text": "iNKT cell graphic", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.124+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "15a33643-57ec-4c67-8668-464ee1ec40fd", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.85, "x": 0.1, "y": 0.25 }, "kind": "list", "text": "Allogeneic Invariant Natural Killer T (iNKT) Cell Platform Leveraging Both Adaptive and Innate Immune Systems; Multiple Near Term Validation Milestones and Clinical Readouts for AGENT-797; Wholly-owned or Exclusively Licensed Pipeline; Proprietary Manufacturing Process; Ability to Investigate iNKT Combinations; Experienced Leadership Team", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.124+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a455b8f9-da29-4a8a-9336-333503761085", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Pioneering Allogeneic iNKT Cell Therapies for Oncology and Other Immune-Mediated Diseases", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.124+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b1c8b06-945c-4443-814c-bb8576cc7aff", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f051391d-867f-4df6-979f-1523781ceb63", "evidence": "The slide is titled 'Pioneering Allogeneic iNKT Cell Therapies for Oncology and Other Immune-Mediated Diseases' and provides a brief overview of the company's platform and milestones.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:55.73473+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "780872d3-6916-4a55-9d3c-80367eb1faef", "evidence": "The slide uses a bulleted list to summarize key company value propositions.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:29.124+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "frameworkName": "list-presentation" } ], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 31, "type": "setup", "title": "This appears to be a closing or transition slide given the slide number 31.", "function": "front_matter", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 5, "componentCount": 2, "textChars": 52, "nDataPoints": 0, "notes": "This appears to be a closing or transition slide given the slide number 31.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:30.493+00", "seconds": 3.51, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/31", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-31", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.5, "x": 0.25, "y": 0.35 }, "kind": "image", "text": "MiNK Therapeutics", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.493+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "99e465fc-bf7e-4600-9472-b6c202c64799", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.02, "y": 0.93 }, "kind": "paragraph", "text": "31 Investor Meetings | October 2021", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.493+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fab5fa1d-7e01-46b0-b7f9-7a41ec6e6654", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "7d766d5d-b996-4d6f-a220-15117180155f", "evidence": "The slide features the company logo and is titled 'MiNK Therapeutics'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:55.816623+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 32, "type": "appendix", "function": "establish_context", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "sparse", "densityScore": 20, "componentCount": 2, "textChars": 300, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:29.517+00", "seconds": 1.907, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/32", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-32", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.75, "x": 0.15, "y": 0.2 }, "kind": "list", "text": "Experienced leadership team\nCEO to sit on the Agenus-MiNK IO Executive Steering Team\nOwnership of IP related to iNKT cells\nAll future inventions of MiNK wholly owned by MiNK; including proprietary manufacturing\nAccess to Agenus checkpoint modulating antibodies", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ba7aa0e-0733-451b-8cad-c03be6eaf000", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.15, "y": 0.05 }, "kind": "title", "text": "MiNK as an Independent Operating Company", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:29.517+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "05547e00-b3af-4ee1-816b-b66c7432a317", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "6cbf9c02-04ca-4a80-81bc-84e3f553f41a", "evidence": "The slide contains list/bullet points describing 'MiNK as an Independent Operating Company'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:46:55.896715+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 33, "type": "resolution", "title": "Uses a balance scale metaphor to represent the modulation between TH1 and TH2 immune responses.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 41, "componentCount": 4, "textChars": 451, "nDataPoints": 0, "notes": "Uses a balance scale metaphor to represent the modulation between TH1 and TH2 immune responses.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:35.001+00", "seconds": 7.382, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/33", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-33", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.84, "x": 0.08, "y": 0.15 }, "kind": "image", "text": "Visual representation of tumor cells, iNKT cell differentiation, donor graft cells, and ARDS-related cells.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:35.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12941fb7-3ce4-420b-b79a-7e588686b6c6", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.35, "x": 0.08, "y": 0.65 }, "kind": "list", "text": "Activation of proinflammatory immunity; Direct killing of diseased cells; Master controller of endogenous cellular immune responses (killing); Turns cold tumors hot", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:35.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1bc1fa0c-af44-4788-bb21-a58a3ebc20ee", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.35, "x": 0.6, "y": 0.65 }, "kind": "list", "text": "Reduce damaging hyperactivation of proinflammatory immune responses; Promote engraftment; Suppress acute GvHD; Aid pathogen clearance", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:35.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f66d592a-b25d-428f-a083-4d1ff065823f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.15, "y": 0.05 }, "kind": "title", "text": "Designed to Address Immunity to Cancer & Beyond", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:35.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f7ce9a8-f05b-47de-bf86-48470efa0af1", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f3a9b9eb-eb0f-4ebf-94f1-8534a1f90931", "evidence": "The slide features list/bullet points outlining the benefits of the iNKT cell therapy, including 'Activation of proinflammatory immunity' and 'Reduce damaging hyperactivation of proinflammatory immune responses'.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:46:55.977972+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "764b76d7-e6d4-47c4-8ea4-a6fea6f03490", "evidence": "Use of a balance scale to represent immune modulation.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 13:20:35.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "frameworkName": "metaphor-analogy" } ], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 34, "type": "resolution", "title": "The slide highlights the strategic use of Agenus' pipeline for combination therapies.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 45, "componentCount": 4, "textChars": 555, "nDataPoints": 0, "notes": "The slide highlights the strategic use of Agenus' pipeline for combination therapies.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:30.57+00", "seconds": 2.679, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/34", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-34", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.78 }, "kind": "callout", "text": "Access to Agenus' Pipeline of Immuno-oncology Antibodies to Generate Effective Combinations for Patients with Cancer", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.57+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f8ca1b4d-3394-4558-8b8a-c085f1e10c1e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.05, "y": 0.92 }, "kind": "disclaimer", "text": "1. Future Planned Trial; 2. Including but not limited to the indications listed", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.57+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5791ba34-c9fc-4629-b233-a9692448a879", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "table", "text": "Indication, AGENT-797 (iNKT cells), Endpoints; Phase 1 r/r Multiple Myeloma, 3+3 up to 1x10^9 iNKT cells, Safety/Persistence/Tumor biomarkers; Phase 1 r/r solid tumors, 3+3 up to 1x10^9 iNKT cells, Safety/Persistence/Clinical benefit; Phase 2, RP2D AGENT-797 + immuno-oncology antibodies, Safety/Clinical benefit", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.57+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1104ec26-43e3-4c46-be9d-e19e183cfaaf", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.15, "y": 0.05 }, "kind": "title", "text": "Phase 1/2 Clinical Trial Focused in Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.57+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8a67fbac-8f8c-44b3-b4e0-8122e7bf184f", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "f65e543c-8248-4575-85d9-037779799ab2", "evidence": "The slide features a table with data on 'Indication', 'AGENT-797 (iNKT cells)', and 'Endpoints' for various clinical trials.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:56.058036+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 34, "from": 14, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "1930f29c-63d8-4add-8285-7c1514ed675c", "evidence": "The document outlines multiple near-term milestones and clinical readouts.", "position": 1, "objective": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies", "confidence": 0.6, "extraction": { "at": "2026-07-17 03:23:31.555372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 35, "type": "analysis", "title": "The slide justifies the clinical trial strategy by citing small sample sizes and surrogate endpoints.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 573, "nDataPoints": 0, "notes": "The slide justifies the clinical trial strategy by citing small sample sizes and surrogate endpoints.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:31.126+00", "seconds": 3.071, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/35", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-35", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.84, "x": 0.08, "y": 0.275 }, "kind": "paragraph", "text": "Acute GVHD is eligible for accelerated development based on efficient clinical trials (ie small sample sizes) and surrogate endpoints (ie response rates)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:31.126+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cab8a3c0-411b-4e0c-8bf5-b4e288f8df21", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.28, "x": 0.06, "y": 0.93 }, "kind": "source-note", "text": "1. Currently in the process of preparing IND application\n2. Including but not limited to the indications listed", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:31.126+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7c201e43-aa56-4fbe-b81a-ab8a08be264d", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.84, "x": 0.08, "y": 0.375 }, "kind": "table", "text": "Indication | AGENT-797 (iNKT cells) | Endpoints\nPhase 1/2 | Acute GVHD | Expected to be 3+3 up to 1x10^9 iNKT cells (AGENT-797) patients undergoing HSCT to evaluate engraftment success and GVHD mitigation | Safety, Persistence, Engraftment success, Response rates", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:31.126+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b2a110b-c9f6-4330-8922-99346ddf514b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.76, "x": 0.12, "y": 0.04 }, "kind": "title", "text": "Phase 1/2 Clinical Trial Focused in Acute GVHD", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:31.126+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ca2cc984-e666-435c-86f7-791db05de369", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "e6068569-f76a-4756-bcb9-1983405a6ec6", "evidence": "The slide features a table with data on 'Indication', 'AGENT-797 (iNKT cells)', and 'Endpoints' for the Phase 1/2 clinical trial in Acute GVHD.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:56.138993+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 35, "name": "Financials", "beatId": "df9de426-4cf6-4a90-b675-ffce826d458b", "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "beatType": { "name": "Financials", "slug": "sequoia-pitch-financials", "status": "active", "canonId": "019dd9b8-245d-74ce-8a5e-8094ec926a75", "version": 1, "description": null }, "evidence": "The document includes data on clinical trials and potential financial opportunities.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 36, "type": "appendix", "title": "The slide details two specific trial arms/phases for the AGENT-797 therapy.", "function": "plan_implementation", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 41, "componentCount": 3, "textChars": 497, "nDataPoints": 2, "notes": "The slide details two specific trial arms/phases for the AGENT-797 therapy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 13:20:30.999+00", "seconds": 2.804, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de071-a0aa-74fc-b780-f72cc7f02158/36", "deck": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158", "deckAnchor": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158#slide-36", "deckJson": "/decks/019de071-a0aa-74fc-b780-f72cc7f02158.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.55, "x": 0.06, "y": 0.93 }, "kind": "source-note", "text": "1. Currently preparing protocol to expand into ARDS secondary other life-threatening infectious diseases, such as influenza. 2. Including but not limited to the indications listed", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.999+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "24713289-627e-4577-8ae1-81963b15c774", "parentComponentId": null }, { "bbox": { "h": 0.48, "w": 0.92, "x": 0.04, "y": 0.24 }, "kind": "table", "text": "Indication, AGENT-797 (iNKT cells), Endpoints. Phase 1 ARDS in COVID-19, 3+3 up to 1x10^9 iNKT cells, Safety/Persistence/Markers/Infections. Phase 1/2 of ARDS in Viral Infections, Expected to be 1x10^9 iNKT cells, Safety/Persistence/Markers/Infections/Intubation", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.999+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6541bf97-c2a1-4733-87bd-dd3d776920bb", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.03 }, "kind": "title", "text": "Phase 1/2 Clinical Trial Focused in Virally Induced ARDS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 13:20:30.999+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c5cb5aca-397f-47d4-9da4-aa9b165d7e8b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "8bf5bbaf-23fb-404b-a096-1c0c8bd6044b", "evidence": "The slide features a table with data on 'Indication', 'AGENT-797 (iNKT cells)', and 'Endpoints' for the Phase 1/2 clinical trial in Virally Induced ARDS.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-16 23:46:56.219599+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 36, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 35, "name": "Financials", "beatId": "df9de426-4cf6-4a90-b675-ffce826d458b", "matchId": "b91a3832-4287-45cb-a936-1168669d75de", "beatType": { "name": "Financials", "slug": "sequoia-pitch-financials", "status": "active", "canonId": "019dd9b8-245d-74ce-8a5e-8094ec926a75", "version": 1, "description": null }, "evidence": "The document includes data on clinical trials and potential financial opportunities.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 36, "from": 5, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "ff1f25c5-6e00-4a50-9457-841955937c0b", "evidence": "The document presents the why, what, and how of MiNK's iNKT cell therapies throughout the deck.", "position": 0, "objective": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work", "confidence": 0.7, "extraction": { "at": "2026-07-17 03:23:31.517263+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true } ], "arcBeats": [ { "from": 5, "to": 5, "label": "Problem", "description": "The document starts by presenting an overview of the problem MiNK Therapeutics aims to solve." }, { "from": 7, "to": 7, "label": "Solution", "description": "The document presents iNKT cells as a distinct solution in the cell therapy landscape." }, { "from": 8, "to": 8, "label": "Pipeline", "description": "The document outlines MiNK's pipeline and milestones." }, { "from": 9, "to": 9, "label": "Team", "description": "The document presents the leadership team with a proven track record." }, { "from": 35, "to": 36, "label": "Financials", "description": "The document includes data on clinical trials and potential financial opportunities." } ], "loops": [ { "from": 5, "to": 36, "label": "Golden Circle", "description": "Why MiNK Therapeutics' iNKT cell therapies are needed and how they work" }, { "from": 14, "to": 34, "label": "Quick Win Big Bet", "description": "Highlighting near-term milestones and clinical readouts as a quick win and a big bet on iNKT cell therapies" } ] }